TICKERNERD
Menu
COYACOYAHealthcare · Biotechnology

COYA Stock Forecast: Coya Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$3.98
−1.97% on the day

The 7 Wall Street analysts covering Coya Therapeutics, Inc. hold a median 12-month price target of $16 — +289.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 28 Oct 2026 — in the upper half.

Market cap
$95.2M
Ticker Nerd rank
67/ 100
Median analyst target
$16
Analysts covering
7
Revenue$244K+49.0% y/y
Operating income−$7.0M
Net income−$6.6M
Free cash flow−$8.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.9%
1M
−20.9%
YTD
−31.4%
1Y
−36.7%
From 52W high
−38.9%
From 52W low
+5.3%
$3.78
$6.51
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

COYA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Coya Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
67/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
92
Revisions
77
Size
74
Quality
60
Value
49
Volatility
48
Momentum
39
Accruals
36
Issuance
32

Growth (92): Sales and profits are climbing, and climbing faster than before.

Issuance (32): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

COYA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on COYA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26COYAHigh $18Median $16Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $12Median $16High $18

The green dot is the last close — the median target sits +289.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 Sept 2026BTIGReiteratesBuy$16
24 Aug 2026Roth CapitalReiteratesBuy$12
24 Aug 2026Roth CapitalReiteratesBuy—
12 Aug 2026Chardan CapitalMaintainsBuy$14
12 Aug 2026Chardan CapitalMaintainsBuy—
12 June 2026Chardan CapitalMaintainsBuy$14
12 June 2026Chardan CapitalMaintainsBuy—
5 June 2026Roth CapitalInitiatesBuy$12
5 June 2026Roth CapitalInitiatesBuy—
10 Apr 2026D. Boral CapitalMaintainsBuy—
23 Mar 2026HC Wainwright & Co.ReiteratesBuy—
19 Mar 2026D. Boral CapitalMaintainsBuy—
16 Mar 2026Chardan CapitalMaintainsBuy—
16 Mar 2026D. Boral CapitalMaintainsBuy—
18 Feb 2026D. Boral CapitalMaintainsBuy—
2 Feb 2026HC Wainwright & Co.ReiteratesBuy—
21 Jan 2026D. Boral CapitalMaintainsBuy—
8 Jan 2026Chardan CapitalMaintainsBuy—
8 Jan 2026D. Boral CapitalMaintainsBuy—
5 Jan 2026D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

COYA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

COYA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Coya Therapeutics, Inc. returned −36.7% against +13.1% for the S&P 500, dividends included.

COYA vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26COYAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

COYA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Coya Therapeutics, Inc. (COYA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.2×

Cheaper than 88% of US stocks

Price / sales
11.9×

Cheaper than 12% of US stocks

Price / book
2.2×

Cheaper than 40% of US stocks

EV / EBITDA
−2.5×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
49.0%

Higher than 85% of US stocks

Earnings growth (YoY)
49.0%

Higher than 74% of US stocks

Gross margin
—
Operating margin
−2890.5%

Higher than 4% of US stocks

Net margin
−270.2%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−60.5%

Higher than 19% of US stocks

Return on assets
−32.3%

Higher than 13% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Coya Therapeutics, Inc. (COYA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Coya Therapeutics, Inc. has a market value of $95.2M and an enterprise value of $52.1M.

  • Revenue in the twelve months to 30 June 2026: $8.0M. The latest quarter grew 49.0% year on year.

  • Net income over the same four quarters: −$21.7M, a −270.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$16.6M.

  • Shares outstanding: 23.5M.

  • Trailing P/E: −3.2×; forward P/E: −2.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Coya Therapeutics, Inc. employs 8 people — $1.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 29 Oct 2026

Data provided by Twelve Data

Peers

COYA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
COYACoya Therapeutics, Inc.$95.2M67
INOInovio Pharmaceuticals, Inc.$95.9M51
ICCCImmuCell Corp.$96.1M94
MISTMilestone Pharmaceuticals, Inc.$94.3M19
PLYXPolaryx Therapeutics, Inc.$94.2M22
NRXSNeurAxis, Inc.$93.7M67
TNXPTonix Pharmaceuticals Holding Corp.$92.1M32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Coya Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest COYA news & analysis

Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS Meeting

Business Wire · 28 Oct 2026neutral

Coya Therapeutics announced that it will present its neurofilament light chain (NfL) biomarker stratification methodology for the ALSTARS trial at the 2026 Annual NEALS Meeting on October 28 in Clearwater, Florida. The presentation will address minimizing the impact of heterogeneity in ALS clinical trials.

Why it matters — The presentation concerns how Coya plans to use NfL biomarker stratification in its ALSTARS trial, relevant to watchers tracking the company’s ALS research.

Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS

Business Wire · 14 Oct 2026positive

Coya Therapeutics plans to initiate an open-label extension of its Phase 2/3 ALSTARS trial evaluating COYA 302 for ALS. The company said the extension is in response to requests from ALSTARS investigators.

Why it matters — The planned extension is a development update for COYA 302 and the ongoing ALSTARS trial.

Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference

Business Wire · 13 Oct 2026neutral

Coya Therapeutics announced that it will participate in a panel discussion at Chardan's 10th Annual Healthcare Conference on October 20 in New York. The panel will focus on neurodegenerative and neuromuscular diseases, including ALS, DMD, and Alzheimer's.

Why it matters — The conference appearance may be of interest to COYA watchers following the company's work in neurodegenerative disorders.

Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS

Business Wire · 5 Oct 2026positive

Coya Therapeutics announced the completion of full enrollment of the planned 120 participants in its Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, its combination of low-dose IL-2 and CTLA-4 Ig, for the potential treatment of amyotrophic lateral sclerosis.

Why it matters — Full enrollment in the pivotal ALSTARS trial moves Coya's lead candidate, COYA 302, a step closer to clinical data for ALS, a key milestone for the company's neurodegenerative disease pipeline.

Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS

Business Wire · 15 Sept 2026positive

Coya Therapeutics announced that the 100th patient has been enrolled in its ongoing Phase 2/3 ALSTARS Trial evaluating COYA 302, its combination of low-dose IL-2 and CTLA-4 Ig, for the treatment of amyotrophic lateral sclerosis. The trial is registered under NCT07161999.

Why it matters — This milestone marks continued progress in the clinical development of Coya's lead candidate COYA 302 for ALS.

FAQ

Frequently asked questions about COYA stock

What is the COYA stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Coya Therapeutics, Inc. have a median 12-month price target of $16, with estimates ranging from $12 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is COYA stock a buy right now?

Of the 7 analysts covering Coya Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Coya Therapeutics, Inc. 67 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank COYA?

As at 28 Oct 2026, Coya Therapeutics, Inc. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (92 of 100).

Will COYA stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +289.4% from the last close, and Ticker Nerd's factor model ranks Coya Therapeutics, Inc. 67 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the COYA stock forecast for 2030?

No analyst covering Coya Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COYA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $18 over the next 12 months.

How has COYA stock performed over the past year?

Coya Therapeutics, Inc. returned -36.7% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Coya Therapeutics, Inc. do?

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs.

What is the latest news on COYA?

The most recent item we track (Business Wire, 28 Oct 2026): "Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS Meeting". Coya Therapeutics announced that it will present its neurofilament light chain (NfL) biomarker stratification methodology for the ALSTARS trial at the 2026 Annual NEALS Meeting on October 28 in Clearwater, Florida. The presentation will address minimizing the impact of heterogeneity in ALS clinical trials.

Company

About Coya Therapeutics, Inc.

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. The company’s current pipeline centers on multiple immune-modulating approaches, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. These programs are designed to address systemic inflammation and neuroinflammation across serious conditions such as neurodegenerative, autoimmune, chronic inflammatory, and metabolic diseases. Coya Therapeutics is particularly active in advancing treatments intended to restore immune balance and support disease-modifying approaches in areas with significant unmet medical need. Based in Houston, Texas, Coya Therapeutics operates within the broader healthcare and biotechnology markets, where its platform-based strategy positions it as a developer of specialized immunotherapy candidates.

CEO Dr. Arun Swaminathan Ph.D. · 8 employees · United States · https://www.coyatherapeutics.com